OncoMatch/Clinical Trials/NCT06048250
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Is NCT06048250 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Mezigdomide for multiple myeloma.
Treatment: Mezigdomide — This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory agent
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: proteasome inhibitor
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: anti-CD38 antibody
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: CAR-T cell therapy (idecabtagene vicleucel)
Receipt of commercially available idecabtagene vicleucel (Abecma) according to FDA approved US Prescribing Information
Cannot have received: mezigdomide (mezigdomide, CC-92480)
Prior exposure to mezigdomide (CC-92480)
Lab requirements
Blood counts
ANC >= 1,500/mm^3 without the use of filgrastim in the previous 3 days; Platelets >= 75,000/mm^3 without platelet transfusion in the previous 3 days
Kidney function
Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin <= 1.5 X ULN (unless has known Gilbert's disease); AST <= 3 x ULN; ALT <= 3 x ULN; Alkaline phosphatase <= 5 x ULN
ANC >= 1,500/mm^3 without the use of filgrastim in the previous 3 days; Platelets >= 75,000/mm^3 without platelet transfusion in the previous 3 days; Total bilirubin <= 1.5 X ULN (unless has known Gilbert's disease); AST <= 3 x ULN; ALT <= 3 x ULN; Alkaline phosphatase <= 5 x ULN; Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify